Lamictal and Visual field defect - a phase IV clinical study of FDA data

Summary:

Visual field defect is reported as a side effect among people who take Lamictal (lamotrigine), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Sabril, and have Complex partial seizures.

The phase IV clinical study analyzes which people have Visual field defect when taking Lamictal. It is created by eHealthMe based on reports of 74,218 people who have side effects when taking Lamictal from the FDA, and is updated regularly.

What is Lamictal?

Lamictal has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 82,626 Lamictal users. Check the latest studies of Lamictal.

What is Visual field defect?

Visual field defect is found to be associated with 767 drugs and 1,037 conditions by eHealthMe. Check the latest studies of Visual field defect.

On Jul, 27, 2026

74,218 people reported to have side effects when taking Lamictal.
Among them, 97 people (0.13%) have Visual field defect.

Could Lamictal cause Visual field defect?

Among these 97 people:

How long have people been on Lamictal when they have Visual field defect? *

What is the gender of people who have Visual field defect when taking Lamictal? *

female: 64.58 %
male: 35.42 %

What is the age of people who have Visual field defect when taking Lamictal? *

What are other drugs people take besides Lamictal? *

What are other side effects people have besides Visual field defect? *

Vision Blurred: 27 people, 27.84%
Blindness: 15 people, 15.46%
Headache (pain in head): 14 people, 14.43%
Dizziness: 14 people, 14.43%
Balance Disorder: 13 people, 13.40%
Visual Impairment: 12 people, 12.37%
Visual Acuity Reduced (reduced clearness of vision): 11 people, 11.34%
Dry Eyes (lack of adequate tears): 9 people, 9.28%
High Blood Pressure: 9 people, 9.28%
Fatigue (feeling of tiredness): 9 people, 9.28%

What are the existing conditions these people have? *

Complex Partial Seizures (epileptic seizure): 16 people, 16.49%
Partial Seizures (seizures which affect only a part of the brain at onset): 11 people, 11.34%
Temporal Lobe Epilepsy (a term that refers to a condition where seizures are generated in the portion of the brain called the temporal lobe): 10 people, 10.31%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 7 people, 7.22%
Insomnia (sleeplessness): 5 people, 5.15%
Pain: 5 people, 5.15%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 4.12%
Grand Mal Convulsion (a type of generalized seizure that affects the entire brain): 4 people, 4.12%
Migraine (headache): 4 people, 4.12%
High Blood Cholesterol: 3 people, 3.09%

* Approximation only. Some reports may have incomplete information.

Do you take Lamictal and have Visual field defect?

- Check whether Visual field defect is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamictal:

Lamictal (82,626 reports)

Browse all side effects of Lamictal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual field defect:

Visual field defect (767 drugs)

Browse all the conditions that are associated with Visual field defect:

Visual field defect (1,037 conditions)

Related publications that referenced our studies

Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lamotrigine (the active ingredients of Lamictal) and Lamictal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.